Chronic Hepatitis C and Insulin Resistance

Understanding the Relationship Between Insulin Resistance and Chronic Hepatitis C Infection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00707603

Enrollment

Registered

2008-07-01

Start date

2006-05-31

Completion date

2008-12-31

Last updated

2015-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Insulin Resistance

Keywords

Insulin resistance, Liver fat, Muscle fat, Abdominal fat, Cytokines

Brief summary

Chronic hepatitis C (CHC) is among the commonest chronic infectious disease in Australia with \>200,000 exposed persons. Amongst non-infectious chronic conditions- Type 2 diabetes, obesity and heart disease are extremely common. This study will examine the relationship between insulin resistance, fat deposition in the liver, muscle and abdomen, and liver injury due to CHC

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

25 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Caucasian male * Age: 25-55 years * Chronic Hepatitis C (PCR positive) and fibrosis ≤ F2 (if liver biopsy done) * Genotypes 1 or 3 * Due to commence antiviral therapy * BMI \< 30

Exclusion criteria

* Cirrhosis or F3 fibrosis on liver biopsy (if done) * \> 20 g ETOH per day * Type 2 Diabetes (need an OGTT if fasting BGL\> 5.7) * Concurrent HIV * Other cause of liver disease

Design outcomes

Primary

Measure	Time frame
Insulin Resistance by euglycaemic hyperinsulinaemic clamp Liver fat, abdominal fat and muscle fat measures	2 years

Secondary

Measure	Time frame
insulin resistance post treatment of Hep C	2 years

Countries

Australia

Outcome results